SCHEMBL9894965

SCHEMBL9894965

CC(=O)c1c(C)nnn1-c1ccc(F)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 8/20 0.63
GABRA5 P31644 3/20 0.45
GABRG2 P18507 2/20 0.45
GABRB3 P28472 2/20 0.45
KCNH2 Q12809 1/20 0.45
LMNA P02545 1/20 0.44
SLC5A1 P13866 1/20 0.43
SLC5A2 P31639 1/20 0.43
TP53 P04637 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA9 Q16790 1/20 0.40
KMT2A Q03164 1/20 0.40
ALDH1A1 P00352 1/20 0.40
GAA P10253 1/20 0.40
MAPT P10636 1/20 0.40
HPGD P15428 1/20 0.40
ALOX15 P16050 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13754468 0.87 PTGS2 (0.55) PTGS2GABRA5GABRG2GABRB3KCNH2
SCHEMBL31297186 0.83 PTGS2 (0.44) PTGS2GABRA5GABRG2GABRB3KCNH2
SCHEMBL9894862 0.82 PTGS2 (0.50) PTGS2GABRA5GABRG2GABRB3KCNH2
SCHEMBL12530467 0.75 PTGS2 (0.60) PTGS2LMNATP53KMT2AALDH1A1
SCHEMBL9895165 0.75 NPSR1 (0.45) PTGS2KMT2AMAPTHPGD
SCHEMBL27915203 0.75 PTGS2 (0.52) PTGS2GABRA5GABRG2GABRB3KCNH2
SCHEMBL15452752 0.74 ALDH1A1 (0.47) PTGS2GABRA5KCNH2TP53ALDH1A1
SCHEMBL2685481 0.72 PTGS2 (0.49) PTGS2GABRA5GABRG2GABRB3KCNH2
SCHEMBL2683661 0.72 PTGS2 (0.49) PTGS2GABRA5GABRG2GABRB3KCNH2
SCHEMBL22897264 0.71 HTT (0.60) PTGS2SLC5A1SLC5A2TP53KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2649064-B1 NOVEL TRIAZOLE COMPOUNDS III HOFFMANN LA ROCHE (CH) 2019-10-02 EP disclosed
EP-2649064-A1 NOVEL TRIAZOLE COMPOUNDS III F. Hoffmann-La Roche AG (CH) 2013-10-16 EP disclosed
US-8466181-B2 1,2,3-triazole-imidazole compounds HOFFMANN-LA ROCHE INC. (US) 2013-06-18 US disclosed
WO-2012076590-A1 NOVEL TRIAZOLE COMPOUNDS III F. HOFFMANN-LA ROCHE AG (CH) 2012-06-14 WO disclosed
US-20120149675-A1 1,2,3-TRIAZOLE-IMIDAZOLECOMPOUNDS HOFFMANN-LA ROCHE INC. 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149675-A1 1,2,3-TRIAZOLE-IMIDAZOLECOMPOUNDS GABRA5, GABRA1, GABRB1 PTGS2 2498/4885GABRA5 1/4885GABRG2 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.